Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Eric Christensen.

Thank you so much for listening today. So always go check out real life pharmacology.com.

We've got a free 31 page PDF. It's a great little study guide, review, whether you're out in practice or whether you're taking board exams or in school,

taking pharmacology exams, go get that absolutely for free. Simply an email. We'll get you access

to that and you can go subscribe at real life pharmacology.com. And as soon as you do that,

you'll get an email with that free 31 page PDF on the top 200 drugs.

So no-brainer to go get that for free.

And again, do that at real-life pharmacology.com.

All right, the drug of the day today is Tycagrilor.

Brand name of this medication is Brilinta.

And this medication is an anti-platelet agent, and it falls in the category similar to clopidigril and prasagrel, which I have covered on previous

podcasts.

So you can go to real-life pharmacology.com and search those if you're looking for more

info on those. But this one we're going to stick with Ticagrelor. So knowing it's from the class

of those other two agents, this is a P2i12 inhibitor. So mechanistically, how this works, it binds adenosine diphosphate,

P2y12 receptor on platelets. And that activity ultimately causes blocking of the function of GP2B- 3A complex, which that complex is necessary, basically for

platelets to stick together and function appropriately. So you'll often hear that referred to as

platelet aggregation. They're starting to collect together and obviously start the formation

of a clot eventually. Uses of this medication, acute coronary syndrome, things like stemmy,

primary prevention after heart attack,

potentially there as well, with aspirin, often called dual anti-platelet therapy.

But there is some caveats to that, and I'll talk about that in a little bit here,

...